Stock Taper
SCREENER COMPARE ANY 2 STOCKS
BLTE
BELITE BIO, INC
NASDAQ
$161.06
▼ DOWN 0.54% (-0.88)

KEY STATISTICS

Market Cap$6.46 B
52w High$200.00
52w Low$62.18
Dividend Yield—
Frequency—
P/E-86.13
Volume111.22K
Shares Out.40.09M

COMPANY

LEADERSHIP

Yu-Hsin Lin
CHIEF EXECUTIVE
Yu-Hsin Lin

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 29, 2022
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
41

PRICE TARGET

Target High$270.00
Target Low$206.00
Target Median$217.00
Target Consensus$224.00

UPCOMING EARNINGS

DateNov 9, 2026
DayMonday
Rev. Est.—
NOV
9
MON

PRICE

$161.06 ▼ DOWN 0.54% (−$0.88)
$161$162$164$1659:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM161.06

About Belite Bio, Inc

https://belitebio.com ↗

Belite Bio, Inc., a San Diego-based clinical-stage biopharmaceutical company, develops therapies for age-related macular degeneration, Stargardt disease, and liver conditions, with lead candidate LBS-008 in Phase 3 trials.

INDUSTRY

Biotechnology

A PRODUCT BELITE BIO, INC IS KNOWN FOR

Tinlarebant (LBS-008)
Tinlarebant (LBS-008)

Tinlarebant, Belite Bio's lead candidate, is a once-daily oral therapy in late-stage trials targeting Stargardt disease and Geographic Atrophy by reducing toxic vitamin A byproducts in the retina.

COMPETITORS

COMPETITOR
ANNX COMPARE
KPRX COMPARE
OCGN COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
10
LISTED HERE
7
RANKED BY POSITION SIZE
SPEM
0.01% · 12.5K
APIE
0.06% · 4.2K
ONEQ
0.01% · 3.7K
BBC
0.71% · 2.3K
EH
EHLS
0.36% · 1.3K
CHIP.L
0.05% · 247
TNXT
0.07% · 74

INSTITUTIONAL OWNERSHIP

SHARES OWNED
23.19%
HOLDERS
93
TOP 12 OF 93 · RANKED BY POSITION SIZE
Darwin Global Management, Ltd.
3.1M sh · $456.1M
Paradigm Biocapital Advisors LP
1.1M sh · $177.74M
Ra Capital Management, L.P.
875.0K sh · $64.75M
Ubs Group AG
768.4K sh · $122.51M
Rtw Investments, LP
715.3K sh · $114.05M
Millennium Management LLC
570.1K sh · $90.89M
Holocene Advisors, LP
494.5K sh · $78.84M
Perceptive Advisors LLC
414.2K sh · $66.26M
Eventide Asset Management, LLC
383.1K sh · $61.28M
Vestal Point Capital, LP
312.5K sh · $23.13M
Deerfield Management Company, L.P. (Series C)
304.0K sh · $48.47M
Point72 Asset Management, L.P.
284.4K sh · $45.5M

RATINGS SNAPSHOT

Overall rating: C-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Lin Yu-Hsin
Sale · 142 shares
2026-08-12
★
DIRECTOR, OFFICER: CHIEF EXECUTIVE OFFICER
Lin Yu-Hsin
Sale · 223 shares
2026-08-12
★
DIRECTOR, OFFICER: CHIEF FINANCIAL OFFICER
Chuang Hao-Yuan
Sale · 223 shares
2026-08-12
★
DIRECTOR, OFFICER: CHIEF FINANCIAL OFFICER
Chuang Hao-Yuan
Sale · 144 shares
2026-08-12

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 2
BUY 2
OUTPERFORM 1
5 GRADES IN THE LAST 12 MONTHS
Cantor Fitzgerald OVERWEIGHT Morgan Stanley OVERWEIGHT HC Wainwright & Co. BUY Mizuho OUTPERFORM Benchmark BUY

SECTORS PEERS

PEERPRICE
PRAX$375.94COMPARE
CRNX$84.69COMPARE
MIRM$96.31COMPARE
LGND$286.29COMPARE
ACAD$29.50COMPARE
DYN$26.10COMPARE
VKTX$33.89COMPARE
ARQT$25.08COMPARE